Publication

Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation

van Roosmalen, MS., Stalmeier, PFM., Verhoef, LCG., Hoekstra-Weebers, JEHM., Oosterwijk, JC., Hoogerbrugge, N., Moog, U. & van Daal, W., 26-Feb-2004, In : British Jounal of Cancer. 90, 2, p. 333-342 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van Roosmalen, MS., Stalmeier, PFM., Verhoef, LCG., Hoekstra-Weebers, JEHM., Oosterwijk, JC., Hoogerbrugge, N., Moog, U., & van Daal, W. (2004). Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. British Jounal of Cancer, 90(2), 333-342. https://doi.org/10.1038/sj.bjc.6601525

Author

van Roosmalen, MS ; Stalmeier, PFM ; Verhoef, LCG ; Hoekstra-Weebers, JEHM ; Oosterwijk, JC ; Hoogerbrugge, N ; Moog, U ; van Daal, W. / Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. In: British Jounal of Cancer. 2004 ; Vol. 90, No. 2. pp. 333-342.

Harvard

van Roosmalen, MS, Stalmeier, PFM, Verhoef, LCG, Hoekstra-Weebers, JEHM, Oosterwijk, JC, Hoogerbrugge, N, Moog, U & van Daal, W 2004, 'Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation', British Jounal of Cancer, vol. 90, no. 2, pp. 333-342. https://doi.org/10.1038/sj.bjc.6601525

Standard

Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. / van Roosmalen, MS; Stalmeier, PFM; Verhoef, LCG; Hoekstra-Weebers, JEHM; Oosterwijk, JC; Hoogerbrugge, N; Moog, U; van Daal, W.

In: British Jounal of Cancer, Vol. 90, No. 2, 26.02.2004, p. 333-342.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van Roosmalen MS, Stalmeier PFM, Verhoef LCG, Hoekstra-Weebers JEHM, Oosterwijk JC, Hoogerbrugge N et al. Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. British Jounal of Cancer. 2004 Feb 26;90(2):333-342. https://doi.org/10.1038/sj.bjc.6601525


BibTeX

@article{82165c7e6a264410af8090365a0f62cc,
title = "Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation",
abstract = "The aim of the study was to evaluate the impact of a decision aid (DA) and its timing in women being tested for a BRCA 1/2 mutation. Women with and without a previous history of cancer were included after blood sampling for genetic testing. The DA consisted of a brochure and video providing information on screening and prophylactic surgery. To evaluate the impact of the DA, women were randomised to the DA group (n = 184), receiving the DA 2 weeks after blood sampling, or to the control group (n = 184). To evaluate the impact of timing, mutation carriers who had received the DA before the test result (n = 47) were compared to mutation carriers who received the DA after the test result (n = 42). Data were collected on well-being, treatment choice, decision and information related outcomes. The impact of the DA was measured 4 weeks after blood sampling. The impact of timing was measured 2 weeks after a positive test result. The DA had no impact on well-being, Regarding decision related outcomes, the DA group more frequently considered prophylactic surgery (P = 0.02) corroborated with higher valuations (P = 0.04). No differences were found for the other decision related outcomes. Regarding information related outcomes, the DA group felt better informed (P = 0.00), was more satisfied with the information (P = 0.00), and showed more accurate risk perceptions. Timing of the DA had no effect on any of the outcomes. No interactions were found between the DA and history of cancer. In conclusion, women being tested for a BRCA 1/2 mutation benefit from the DA on information related outcomes. Because timing had no effect, the DA is considered useful either before or after the test result.",
keywords = "decision aid, randomised trial, BRCA1, BRCA2, HEREDITARY BREAST-CANCER, OVARIAN-CANCER, FAMILY HISTORY, FOLLOW-UP, SUSCEPTIBILITY, DISTRESS, IMPACT, RISK, OOPHORECTOMY, CARRIERS",
author = "{van Roosmalen}, MS and PFM Stalmeier and LCG Verhoef and JEHM Hoekstra-Weebers and JC Oosterwijk and N Hoogerbrugge and U Moog and {van Daal}, W",
year = "2004",
month = feb,
day = "26",
doi = "10.1038/sj.bjc.6601525",
language = "English",
volume = "90",
pages = "333--342",
journal = "British Jounal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

RIS

TY - JOUR

T1 - Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation

AU - van Roosmalen, MS

AU - Stalmeier, PFM

AU - Verhoef, LCG

AU - Hoekstra-Weebers, JEHM

AU - Oosterwijk, JC

AU - Hoogerbrugge, N

AU - Moog, U

AU - van Daal, W

PY - 2004/2/26

Y1 - 2004/2/26

N2 - The aim of the study was to evaluate the impact of a decision aid (DA) and its timing in women being tested for a BRCA 1/2 mutation. Women with and without a previous history of cancer were included after blood sampling for genetic testing. The DA consisted of a brochure and video providing information on screening and prophylactic surgery. To evaluate the impact of the DA, women were randomised to the DA group (n = 184), receiving the DA 2 weeks after blood sampling, or to the control group (n = 184). To evaluate the impact of timing, mutation carriers who had received the DA before the test result (n = 47) were compared to mutation carriers who received the DA after the test result (n = 42). Data were collected on well-being, treatment choice, decision and information related outcomes. The impact of the DA was measured 4 weeks after blood sampling. The impact of timing was measured 2 weeks after a positive test result. The DA had no impact on well-being, Regarding decision related outcomes, the DA group more frequently considered prophylactic surgery (P = 0.02) corroborated with higher valuations (P = 0.04). No differences were found for the other decision related outcomes. Regarding information related outcomes, the DA group felt better informed (P = 0.00), was more satisfied with the information (P = 0.00), and showed more accurate risk perceptions. Timing of the DA had no effect on any of the outcomes. No interactions were found between the DA and history of cancer. In conclusion, women being tested for a BRCA 1/2 mutation benefit from the DA on information related outcomes. Because timing had no effect, the DA is considered useful either before or after the test result.

AB - The aim of the study was to evaluate the impact of a decision aid (DA) and its timing in women being tested for a BRCA 1/2 mutation. Women with and without a previous history of cancer were included after blood sampling for genetic testing. The DA consisted of a brochure and video providing information on screening and prophylactic surgery. To evaluate the impact of the DA, women were randomised to the DA group (n = 184), receiving the DA 2 weeks after blood sampling, or to the control group (n = 184). To evaluate the impact of timing, mutation carriers who had received the DA before the test result (n = 47) were compared to mutation carriers who received the DA after the test result (n = 42). Data were collected on well-being, treatment choice, decision and information related outcomes. The impact of the DA was measured 4 weeks after blood sampling. The impact of timing was measured 2 weeks after a positive test result. The DA had no impact on well-being, Regarding decision related outcomes, the DA group more frequently considered prophylactic surgery (P = 0.02) corroborated with higher valuations (P = 0.04). No differences were found for the other decision related outcomes. Regarding information related outcomes, the DA group felt better informed (P = 0.00), was more satisfied with the information (P = 0.00), and showed more accurate risk perceptions. Timing of the DA had no effect on any of the outcomes. No interactions were found between the DA and history of cancer. In conclusion, women being tested for a BRCA 1/2 mutation benefit from the DA on information related outcomes. Because timing had no effect, the DA is considered useful either before or after the test result.

KW - decision aid

KW - randomised trial

KW - BRCA1

KW - BRCA2

KW - HEREDITARY BREAST-CANCER

KW - OVARIAN-CANCER

KW - FAMILY HISTORY

KW - FOLLOW-UP

KW - SUSCEPTIBILITY

KW - DISTRESS

KW - IMPACT

KW - RISK

KW - OOPHORECTOMY

KW - CARRIERS

U2 - 10.1038/sj.bjc.6601525

DO - 10.1038/sj.bjc.6601525

M3 - Article

C2 - 14735173

VL - 90

SP - 333

EP - 342

JO - British Jounal of Cancer

JF - British Jounal of Cancer

SN - 0007-0920

IS - 2

ER -

ID: 4171791